Hoth Therapeutics, Inc. (NASDAQ:HOTH) was founded on May 16, 2001, headquartered in New York, New York, USA, with 2 full-time employees (2/1/2019). It is a development stage biopharmaceutical company focusing on Targeted therapy for patients suffering from conditions such as atopic dermatitis (also called eczema).
Hoth Therapeutics, Inc. (HOTH):
Hoth Therapeutics is committed to the development of targeted therapies for atopic dermatitis. Its main asset is a relicensing agreement signed with Chelexa Biosciences, Inc., under which Chelexa grants Hoth an exclusive subordinate license to use its BioLexa platform, the BioLexa platform It is a patented patented pharmaceutical compound platform developed by the University of Cincinnati.
On May 26, 2017, Hoth Therapeutics signed a relicensing agreement with Chelexa, which was amended on August 22, 2018 and August 29, 2018. Accordingly, Chelexa granted the company to manufacture, use, import, and sell Exclusive sublicense agreement; and sell products based on or involving the use of (i) topical compositions containing zinc chelating agents and gentamicin and (ii) zinc chelating agents to inhibit biofilm formation (“BioLexa platform” or “BioLexa” ), the right was originally granted to Chelexa by the University of Cincinnati. In addition, Chelexa granted Hoth Therapeutics the exclusive and non-exclusive sublicense (the right to further sublicense to third parties) based on the BioLexa platform to distribute, use, produce, import, and sell products.
The initial focus of Hoth Therapeutics is to use the BioLexa platform to develop two topical cream products. The first is used to treat eczema; the second topical cream, after application, aims to reduce postoperative infections, accelerate healing and improve acceptance Clinical results of patients undergoing cosmetic dermatological procedures.
In addition, Hoth Therapeutics intends to conduct a preliminary study on the effect of BioLexa in accelerating the healing of diabetic wounds.
The BioLexa platform combines a zinc chelator approved by the US Food and Drug Administration (“FDA”) with one or more topical approved antibiotics to prevent the formation of infectious biofilms and the resulting blockage of sweat ducts. Symptoms to resolve unchecked eczema attacks. As far as the company knows, this is the first medicine to prevent eczema.
Hoth Therapeutics, Inc. (HOTH) investment:
Hoth Therapeutics, Inc. (NASDAQ:HOTH) submitted its IPO prospectus on 10/10/2018 and listed on Nasdaq on 2/15/2019 with an issue price of US$5.6. It issued 1.25 million shares and raised 7 million shares. Underwriting by Laidlaw & Company (UK) Ltd.